| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/26/2002 | US6362190 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, n'-((1-(aminoiminomethyl)4-piperidinyl) methyl)-n-(3,3-diphenylpropionyl)-l-proline amide |
| 03/26/2002 | US6362186 Aminoalkyl substituted 9H-phridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives |
| 03/26/2002 | US6362182 Hypotensive agents; anticholesterol agents; benign prostatic hypertropic |
| 03/26/2002 | US6362180 Antagonist to corticotropin releasing factor |
| 03/26/2002 | US6362173 Methods for treating psychosis associated with cocaine addiction with glucocorticoid receptor antagonists |
| 03/26/2002 | US6362161 Copolymer-1 improvements on compositions of copolymers |
| 03/26/2002 | US6361957 Assay for D-serine transport antagonist and use for treating psychosis |
| 03/26/2002 | US6361771 Implantable cell culture device comprising semipermeable membrane permitting diffusion of growth factor therethrough, and arpe-19 cells genetically engineered to produce growth factor disposed within semipermeable membrane |
| 03/26/2002 | CA2333024C Method for the treatment of insomnia |
| 03/26/2002 | CA2094703C Substituted piperazines as central nervous system agents |
| 03/26/2002 | CA2034096C Controlled absorption naproxen formulation for once-daily administration |
| 03/26/2002 | CA2032498C Novel 8-substituted-2-aminotetralines |
| 03/22/2002 | CA2357306A1 Fused ring system containing indole as m4 selective aza-anthracene muscarinic receptor antagonists |
| 03/21/2002 | WO2002022819A2 Calcium binding proteins |
| 03/21/2002 | WO2002022805A2 Modulation of il-2- and il-15-mediated t cell responses |
| 03/21/2002 | WO2002022801A2 Mammalian receptor genes and uses |
| 03/21/2002 | WO2002022794A2 ENDOTHELIN CONVERTING ENZYMES AND THE AMYLOID βPEPTIDE |
| 03/21/2002 | WO2002022684A2 Transporters and ion channels |
| 03/21/2002 | WO2002022682A1 Interferon-alpha induced gene |
| 03/21/2002 | WO2002022665A1 Novel g protein-coupled receptor proteins and dnas tehreof |
| 03/21/2002 | WO2002022658A2 Muteins of the cgrp 1-7 peptide fragment and use thereof as nicotinic neuronal receptor enhancers |
| 03/21/2002 | WO2002022647A1 Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids |
| 03/21/2002 | WO2002022630A1 Purine derivatives |
| 03/21/2002 | WO2002022627A2 Ligands for metabotropic glutamate receptors |
| 03/21/2002 | WO2002022611A2 Caspase inhibitors and uses thereof |
| 03/21/2002 | WO2002022610A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | WO2002022609A1 Process for producing paroxetine salt containing substantially no organic solvent |
| 03/21/2002 | WO2002022608A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022607A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022606A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022605A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022604A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022603A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022602A2 Triazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022601A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022588A1 Novel pyrimidine derivative and novel pyridine derivative |
| 03/21/2002 | WO2002022581A1 Nitrogen-containing compounds and their use as glycine transport inhibitors |
| 03/21/2002 | WO2002022579A2 Antipsychotic sulfonamide-heterocycles, and methods of use thereof |
| 03/21/2002 | WO2002022574A1 Tricyclic heterocyclic compound, process for producing the same, and use thereof |
| 03/21/2002 | WO2002022573A2 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | WO2002022572A2 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | WO2002022562A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022561A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022558A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022551A1 Derivatives of naphthalene with comt inhibiting activity |
| 03/21/2002 | WO2002022212A2 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | WO2002022204A2 Transdermal electrotransport device and method for manufacturing same |
| 03/21/2002 | WO2002022170A1 Insulin secretion controlling agents |
| 03/21/2002 | WO2002022166A2 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | WO2002022162A1 Remedies for amyotrophic lateral sclerosis |
| 03/21/2002 | WO2002022150A2 Medicament containing activated antithrombin iii |
| 03/21/2002 | WO2002022149A1 Use of il-6r/il-6 chimera in huntington's disease |
| 03/21/2002 | WO2002022143A1 A pharmaceutical composition for treating headache disease and process and uses thereof |
| 03/21/2002 | WO2002022141A2 Xenon as medicament |
| 03/21/2002 | WO2002022135A1 Creatine ester pronutrient compounds and formulations |
| 03/21/2002 | WO2002022129A1 A method of analgesia |
| 03/21/2002 | WO2002022114A2 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 03/21/2002 | WO2002022112A2 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/21/2002 | WO2002022111A2 Combination of lipoic acids and conjugated acids for treating diabetic disorders |
| 03/21/2002 | WO2002011712A8 Combination of huperzine and nicotinic compounds as a neuroprotective agent |
| 03/21/2002 | WO2002004457A8 Azepino[4,5-b]pyrano[3,2-e]indoles |
| 03/21/2002 | WO2002000659A3 Methods of synthesis for 9-substituted hypoxanthine derivatives |
| 03/21/2002 | WO2001095920A8 Composition comprising clinoptolite, plant extracts and vitamin b complex for diabetic neuropathy |
| 03/21/2002 | WO2001081346A3 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 03/21/2002 | WO2001078760A3 Method for treating pain by peripheral administration of a neurotoxin |
| 03/21/2002 | WO2001078703A3 Methods and compositions for modulating alpha adrenergic receptor activity |
| 03/21/2002 | WO2001078702A3 Methods and compositions for modulating alpha adrenergic receptor activity |
| 03/21/2002 | WO2001074902A3 Adenine binding g protein coupled receptors |
| 03/21/2002 | WO2001074365A3 An efficacious dosage regimen of galantamine that reduces side effects |
| 03/21/2002 | WO2001070694A8 Amorphous torasemide modification |
| 03/21/2002 | WO2001070672A3 Compounds and methods to treat alzheimer's disease |
| 03/21/2002 | WO2001068859A3 Il-17 receptor like molecules and uses thereof |
| 03/21/2002 | WO2001068700A3 Regulation of human substance p-like g protein-coupled receptor |
| 03/21/2002 | WO2001068568A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001064837A3 β NETRIN AND USES THEREOF |
| 03/21/2002 | WO2001064165A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001055106A3 Novel melanocortin receptor agonists and antagonists |
| 03/21/2002 | WO2001051638A3 Drug metabolizing enzymes |
| 03/21/2002 | WO2001041749A3 Combinations of sumatriptan or naratriptan with cyclooxygenase iiinhibitor |
| 03/21/2002 | WO2001038567A3 Genetic indicators of tobacco consumption |
| 03/21/2002 | WO2001037832A3 Combination of riluzole and gabapentin and use thereof as medicine |
| 03/21/2002 | WO2001035943A3 Dextrose and insulin fluid formulation for intravenous infusion |
| 03/21/2002 | WO2001034136A3 Use of adatanserin for the treatment of neurodegenerative conditions |
| 03/21/2002 | WO2001030375A3 Use of gdnf for treating corneal defects |
| 03/21/2002 | WO2001026736A3 Intraspinal compositions containing botulinum toxin for treating pain |
| 03/21/2002 | WO2001014372A3 Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent |
| 03/21/2002 | WO2000041484A8 Novel use of phospholipids of vegetable and animal origin in nutritional therapy |
| 03/21/2002 | US20020035737 Cloning pigs using donor nuclei from differentiated cells |
| 03/21/2002 | US20020035735 Reproducing and animal; obtain preferential embryonic cells, culture cells, transfer cells to primate, recover infant |
| 03/21/2002 | US20020035277 Using Grignard reagent; antidepressant |
| 03/21/2002 | US20020035262 7-hetero-bicyclo[2.2.1]-heptanes |
| 03/21/2002 | US20020035147 Nervous system, psychological disorders |
| 03/21/2002 | US20020035145 Administering mixture of alanine, serine, methylglycine and cycloserine |
| 03/21/2002 | US20020035140 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/21/2002 | US20020035132 Tetrahydropyran derivatives and their use as therapeutic agents |
| 03/21/2002 | US20020035130 Antidepressants, therapy for Parkinson's disease |
| 03/21/2002 | US20020035129 Cholinesterase inhibitor |
| 03/21/2002 | US20020035128 Cholinesterase inhibitors |
| 03/21/2002 | US20020035123 For treating pain or memory deficiencies related to Alzheimer's disease and other neurodegenerative disorders associated with aging |
| 03/21/2002 | US20020035122 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives |